Post-Approval Efficacy Studies: EMA Explains The Options
This article was originally published in SRA
Executive Summary
The European Medicines Agency has published a draft guideline explaining in more detail the circumstances under which companies can be required to conduct a post-authorization efficacy study (PAES), and how to go about designing such a study in order to collect further data on aspects of a drug's benefit-risk profile1.